nivolumab,ipilimumab
bms
['niche-2']
 niche-2 study evaluating 4 weeks of preop immunotherapy for dmmr colon cancer with 74% staged as high risk stage 3. remarkable major path response of 95% and pcr of 67%. now that s a waterfall plot! #esmo22 presidential symposium 
Professor | Vice Chair of Clinical Research & Faculty Development | Thoracic & GI cancer researcher | Rutgers Cancer Institute of New Jersey | opinions my own